Non-Hodgkin lymphoma epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Non-Hodgkin lymphoma}}
{{Non-Hodgkin lymphoma}}
{{CMG}}; {{AE}} {{Rim}}, {{AS}}
{{CMG}}; {{AE}}  
 
==Overview==
==Overview==
Non-Hodgkin lymphoma (NHL)  accounts for about 4% of all cancers in the United States. American cancer society statistic center estimates the incidence of non Hodgkin's lymphoma as 74680 in the year 2018, the incidence rate was estimated to 19 in 100,000 individuals in the years 2010-2014. The age-adjusted [[prevalence]] of non-Hodgkin lymphoma is 131.1 per 100,000 individuals in 2011.


==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
===Prevalence===
===Prevalence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.


* In the United States, the age-adjusted [[prevalence]] of non-Hodgkin lymphoma is 131.1 per 100,000 individuals in 2011.<ref name="pmid25655604">{{cite journal |vauthors=Chiu BC, Hou N |title=Epidemiology and etiology of non-hodgkin lymphoma |journal=Cancer Treat. Res. |volume=165 |issue= |pages=1–25 |date=2015 |pmid=25655604 |doi=10.1007/978-3-319-13150-4_1 |url=}}</ref>
===Case-fatality rate/Mortality rate===
===Incidence===
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
* In the year 2018  the incidence of non-Hodgkin lymphoma was estimated to be 74680.
*The case-fatality rate/mortality rate of [disease name] is approximately [number range].
 
* Between  2010-2014, the incidence of non-Hodgkin lymphoma was estimated to be 19 cases per 100,000 individuals in the United States.<ref name="urlAmerican Cancer Society | Cancer Facts & Statistics">{{cite web |url=https://cancerstatisticscenter.cancer.org/#!/cancer-site/Non-Hodgkin%20lymphoma |title=American Cancer Society &#124; Cancer Facts & Statistics |format= |work= |accessdate=}}</ref><ref>Adult Non-Hodgkin Lymphoma Treatment. National Cancer Institute. http://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq Accessed on October 1, 2015</ref>
* The delay-adjusted [[incidence]] of non-Hodgkin lymphoma in 2011 was estimated to be 20.2 per 100,000 individuals in the United States.
* In 2011, the age-adjusted [[incidence]] of non-Hodgkin lymphoma was 19.63 per 100,000 individuals in the United States.<ref name="pmid25655604">{{cite journal |vauthors=Chiu BC, Hou N |title=Epidemiology and etiology of non-hodgkin lymphoma |journal=Cancer Treat. Res. |volume=165 |issue= |pages=1–25 |date=2015 |pmid=25655604 |doi=10.1007/978-3-319-13150-4_1 |url=}}</ref><ref name="pmid25864967">{{cite journal |vauthors=Chihara D, Nastoupil LJ, Williams JN, Lee P, Koff JL, Flowers CR |title=New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy |journal=Expert Rev Anticancer Ther |volume=15 |issue=5 |pages=531–44 |date=May 2015 |pmid=25864967 |pmc=4698971 |doi=10.1586/14737140.2015.1023712 |url=}}</ref>


===Age===
===Age===
* While the overall age-adjusted [[incidence]] of non-Hodgkin lymphoma in the United States between 2007 and 2011 is 19.7 per 100,000 individuals, the age-adjusted [[incidence]] of non-Hodgkin lymphoma by age category is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
*Patients of all age groups may develop [disease name].
** Under 65 years: 9.3 per 100,000
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
** 65 and over: 91.5 per 100,000
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age.  
 
*[Chronic disease name] is usually first diagnosed among [age group].
* Shown below is an image depicting the incidence of non-Hodgkin lymphoma by the age of diagnosis in males in the United States between 1975 and 1977 as well as between 2009 and 2011.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
*[Acute disease name] commonly affects [age group].
 
[[File:Incidence of non Hodgkin lymphoma by the age of diagnosis in males, USA.PNG|700px|Incidence of non Hodgkin lymphoma by the age of diagnosis in males, USA.PNG]]


===Race===
*There is no racial predilection to [disease name].
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
===Gender===
===Gender===
* Males are more commonly affected with non-Hodgkin lymphoma than females
*[Disease name] affects men and women equally.
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.


* In the United States, the age-adjusted  [[incidence]]  of non-Hodgkin lymphoma by gender in 2011 is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
===Region===
** In males: 112.3 per 100,000 individuals
*The majority of [disease name] cases are reported in [geographical region].
** In females: 76.9 per 100,000 individuals


* In the United States, the delay-adjusted [[incidence]] of non-Hodgkin lymphoma by gender in 2011 is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
** In males: 24.77 per 100,000 individuals
** In females: 16.58 per 100,000 individuals


* Shown below is an image depicting the delay-adjusted [[incidence]] and observed [[incidence]] of non-Hodgkin lymphoma by gender and race in the United States between 1975 and 2011.  These graphs are adapted from [[SEER]]: The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
===Developed Countries===


[[Image:Incidence of non Hodgkin lymphoma by gender and race in USA.PNG|Delay-adjusted [[incidence]] and observed [[incidence]] of non-Hodgkin lymphoma by gender and race in the United States between 1975 and 2011]]
===Developing Countries===
 
===Race===
 
* Shown below is a table depicting the age-adjusted [[prevalence]] of non-Hodgkin lymphoma by race in 2011 in the United States.<ref name="pmid25655604">{{cite journal |vauthors=Chiu BC, Hou N |title=Epidemiology and etiology of non-hodgkin lymphoma |journal=Cancer Treat. Res. |volume=165 |issue= |pages=1–25 |date=2015 |pmid=25655604 |doi=10.1007/978-3-319-13150-4_1 |url=}}</ref>
 
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
|-
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" | || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''All Races''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''White''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Black''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Asian/Pacific Islander'''  || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Hispanic'''
|-
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Age-adjusted [[prevalence]]'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |131.1 per 100,000 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |141.2 per 100,000|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |95.3 per 100,000|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |83.5 per 100,000|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |101.4 per 100,000
|}
 
* Shown below is an image depicting the [[incidence]] of non-Hodgkin lymphoma by race in the United States between 1975 and 2011.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
 
[[Image:Incidence of non Hodgkin lymphoma by race.PNG|Incidence of non-Hodgkin lymphoma by race in the United States between 1975 and 2011]]
 
<small> API: Asian/Pacific Islander; AI/AN: American Indian/ Alaska Native</small>


==References==
==References==
{{reflist|2}}
{{Reflist|2}}
 
{{Hematology}}
{{Hematological malignancy histology}}
 
[[Category:Hematology]]
[[Category:Types of cancer]]
[[Category:Disease]]


{{WikiDoc Help Menu}}
[[Category:Up-To-Date]]
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Medicine]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Immunology]]
[[Category:Immunology]]

Revision as of 23:53, 19 January 2019

Non-Hodgkin lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Non-Hodgkin's Lymphoma

Differentiating Non-Hodgkin Lymphoma from Other Diseases
Differentiating Types of Non-Hodgkin's Lymphoma

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Biopsy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Non-Hodgkin lymphoma epidemiology and demographics On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non-Hodgkin lymphoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non-Hodgkin lymphoma epidemiology and demographics

CDC on Non-Hodgkin lymphoma epidemiology and demographics

Non-Hodgkin lymphoma epidemiology and demographics in the news

Blogs on Non-Hodgkin lymphoma epidemiology and demographics

Directions to Hospitals Treating Non-Hodgkin lymphoma

Risk calculators and risk factors for Non-Hodgkin lymphoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Epidemiology and Demographics

Incidence

  • The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
  • In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

Prevalence

  • The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
  • In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
  • The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

Case-fatality rate/Mortality rate

  • In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
  • The case-fatality rate/mortality rate of [disease name] is approximately [number range].

Age

  • Patients of all age groups may develop [disease name].
  • The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
  • [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
  • [Chronic disease name] is usually first diagnosed among [age group].
  • [Acute disease name] commonly affects [age group].

Race

  • There is no racial predilection to [disease name].
  • [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

Gender

  • [Disease name] affects men and women equally.
  • [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.

Region

  • The majority of [disease name] cases are reported in [geographical region].
  • [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Developed Countries

Developing Countries

References